BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38180018)

  • 1. Analyzing risk factors and developing a stratification system for hepatocellular carcinoma recurrence after interferon-free direct-acting antiviral therapy in chronic hepatitis C patients.
    Luan CH; Su PS; Chu CJ; Lin CC; Su CW; Luo JC; Lee IC; Chi CT; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
    J Chin Med Assoc; 2024 Apr; 87(4):357-368. PubMed ID: 38180018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma.
    Chen YS; Huang KH; Wang PM; Chuang CH; Yong CC; Liu YW; Huang PY; Yao CC; Lin YP; Tsai MC
    Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208582
    [No Abstract]   [Full Text] [Related]  

  • 3. Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.
    Mashiba T; Joko K; Kurosaki M; Ochi H; Osaki Y; Kojima Y; Nakata R; Goto T; Takehiro A; Kimura H; Mitsuda A; Kawanami C; Uchida Y; Ogawa C; Kusakabe A; Narita R; Ide Y; Abe T; Tsuji K; Kitamura T; Okada K; Sohda T; Shigeno M; Satou T; Izumi N
    PLoS One; 2018; 13(4):e0194704. PubMed ID: 29659591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy.
    Nagaoki Y; Imamura M; Nishida Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Fujino H; Nakahara T; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Miki D; Hiyama Y; Ochi H; Chayama K; Aikata H
    J Med Virol; 2019 Apr; 91(4):650-658. PubMed ID: 30381831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
    Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K
    J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan.
    Chi CT; Chen CY; Su CW; Chen PY; Chu CJ; Lan KH; Lee IC; Hou MC; Huang YH
    J Microbiol Immunol Infect; 2021 Jun; 54(3):385-395. PubMed ID: 31771822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual risk of hepatocellular carcinoma development for chronic hepatitis C patients treated by all oral direct-acting antivirals with sustained virological response.
    Luan CH; Su PS; Chu CJ; Lin CC; Su CW; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
    J Chin Med Assoc; 2023 Sep; 86(9):795-805. PubMed ID: 37466658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
    Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors for hepatocellular carcinoma occurrence or recurrence after direct-acting antiviral agents in patients with chronic hepatitis C.
    Yoshimasu Y; Furuichi Y; Kasai Y; Takeuchi H; Sugimoto K; Nakamura I; Itoi T
    J Gastrointestin Liver Dis; 2019 Mar; 28(1):63-71. PubMed ID: 30851174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents.
    Zou WY; Choi K; Kramer JR; Yu X; Cao Y; El-Serag HB; Kanwal F
    Dig Dis Sci; 2019 Nov; 64(11):3328-3336. PubMed ID: 31041639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
    Kuwano A; Yada M; Nagasawa S; Tanaka K; Morita Y; Masumoto A; Motomura K
    J Viral Hepat; 2022 Jan; 29(1):35-42. PubMed ID: 34661320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.
    Ikeda K; Kawamura Y; Kobayashi M; Kominami Y; Fujiyama S; Sezaki H; Hosaka T; Akuta N; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Dig Dis Sci; 2017 Oct; 62(10):2932-2942. PubMed ID: 28884320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct-acting antivirals.
    Ogawa E; Nakamuta M; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Ooho A; Azuma K; Takahashi K; Satoh T; Koyanagi T; Yamashita N; Ichiki Y; Yamashita N; Kuniyoshi M; Yanagita K; Amagase H; Morita C; Sugimoto R; Kato M; Shimoda S; Nomura H; Hayashi J;
    J Gastroenterol Hepatol; 2022 Jan; 37(1):190-199. PubMed ID: 34374128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study.
    Nakano M; Koga H; Ide T; Kuromatsu R; Hashimoto S; Yatsuhashi H; Seike M; Higuchi N; Nakamuta M; Shakado S; Sakisaka S; Miuma S; Nakao K; Yoshimaru Y; Sasaki Y; Oeda S; Eguchi Y; Honma Y; Harada M; Nagata K; Mawatari S; Ido A; Maeshiro T; Matsumoto S; Takami Y; Sohda T; Torimura T
    Cancer Med; 2019 May; 8(5):2646-2653. PubMed ID: 30900818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
    Ohki T; Sato K; Kondo M; Goto E; Sato T; Kondo Y; Akamatsu M; Sato S; Yoshida H; Koike Y; Obi S
    J Viral Hepat; 2021 Nov; 28(11):1597-1603. PubMed ID: 34312954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Interferon-free Direct-acting Antiviral Therapy on Primary Hepatocellular Carcinoma Recurrence: A Landmark Time Analysis and Time-dependent Extended Cox Proportional Hazards Model Analysis.
    Miuma S; Miyamoto J; Taura N; Fukushima M; Sasaki R; Haraguchi M; Shibata H; Sato S; Miyaaki H; Nakao K
    Intern Med; 2020; 59(7):901-907. PubMed ID: 32238660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
    Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ
    J Hepatol; 2017 Dec; 67(6):1204-1212. PubMed ID: 28802876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study.
    Ji D; Chen GF; Niu XX; Zhang M; Wang C; Shao Q; Wu V; Wang Y; Cheng G; Hurwitz SJ; Schinazi RF; Lau G
    Metabol Open; 2021 Jun; 10():100090. PubMed ID: 33889834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment.
    Ogawa E; Furusyo N; Nomura H; Dohmen K; Higashi N; Takahashi K; Kawano A; Azuma K; Satoh T; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J;
    Aliment Pharmacol Ther; 2018 Jan; 47(1):104-113. PubMed ID: 29035002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
    J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.